Entropy CEO Jason Carroll said, “The DSMB’s recommendation to progress to Cohort 2 without any protocol changes is an important milestone for the TRP-8803 program and provides independent validation of the favourable safety profile observed in Cohort 1.”
Entropy Neurodynamics clears safety hurdle for IV psilocin trial in binge eating disorder
June 15, 2026 Australian Biotech
Latest Video
New Stories
-
The 'Dispatched' Podcast - Season 5, Episode 22
July 3, 2026 - - Podcast -
Is that a subtle but meaningful shift conceding the potential need for a response to global realities?
July 3, 2026 - -
New once weekly therapy offers extended protection for people with haemophilia A
July 3, 2026 - - Latest News -
Nothing else grows below this self-serving and broken institutional framework
July 3, 2026 - - Latest News -
Nurse prescribing reform set to expand access to PBS subsidised medicines
July 3, 2026 - - Latest News -
Medicines Australia chief says next negotiation is about getting comfortable with being uncomfortable
July 3, 2026 - - Latest News -
Minister looks to be sending a very clear message about these therapies and the PBS
July 2, 2026 - - Latest News

